Barinthus Biotherapeutics (BRNS) Change in Receivables (2020 - 2023)
Barinthus Biotherapeutics' (BRNS) quarterly Change in Receivables came in at -$194000.0 in Q3 2023, up 98.21% YoY from -$97873.7 in Q3 2022, and up 69.92% on a QoQ basis from -$645000.0 in Q2 2023.
Barinthus Biotherapeutics (BRNS) Change in Receivables (2020 - 2023) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 4 years of Change in Receivables data on file, last reported at -$194000.0 in Q3 2023.
- Quarterly Change in Receivables rose 98.21% year-over-year to -$194000.0 in Q3 2023, while the trailing twelve-month figure through Jun 2024 was -$194000.0 (up 98.85% YoY) and the FY2023 annual result came in at -$5.8 million, down 199.43% from the prior year.
- Change in Receivables improved to -$194000.0 in Q3 2023, from -$645000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $18.4 million in Q1 2022 to a low of -$10.9 million in Q3 2022.
- A 4-year average of -$67000.0 and a median of -$284000.0 in 2021 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 8923.08% in 2022, down 181200.0% in 2022.
- Tracing BRNS's Change in Receivables over 4 years: stood at $448000.0 in 2020, then plunged by 116.29% to -$73000.0 in 2021, then tumbled by 350.68% to -$329000.0 in 2022, then jumped by 41.03% to -$194000.0 in 2023.
- The last three Change in Receivables figures came in at -$194000.0 (Q3 2023), -$645000.0 (Q2 2023), and -$5.0 million (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -194,000.00 |
| Sep 30, 2023 | -194,000.00 |
| Jun 30, 2023 | -645,000.00 |
| Jun 30, 2023 | -645,000.00 |
| Mar 31, 2023 | -4.96 Mn |
| Mar 31, 2023 | -4.96 Mn |
| Dec 31, 2022 | -329,000.00 |
| Dec 31, 2022 | -329,000.00 |
| Sep 30, 2022 | -10.87 Mn |
| Sep 30, 2022 | -10.87 Mn |
| Jun 30, 2022 | -1.32 Mn |
| Jun 30, 2022 | -1.32 Mn |
| Mar 31, 2022 | 18.35 Mn |
| Mar 31, 2022 | 18.35 Mn |
| Dec 31, 2021 | -73,000.00 |
| Dec 31, 2021 | -73,000.00 |
| Sep 30, 2021 | 6,000.00 |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | -284,000.00 |
| Jun 30, 2021 | -284,000.00 |